Induction of Metabolic Hypofunction and Neurochemical Deficits after Chronic Intermittent Exposure to Phencyclidine: Differential Modulation by Antipsychotic Drugs
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sokoloff, L., Reivich, M., Kennedy, C., Rosiers, M. H. D., Patlak, C. S., Pettigrew, K. D., Sakurada, O., & Shinohara, M. (1977) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1977.tb10649.x · Cited by 6,000 · cited 2×
“We used the technique of quantitative 14C-2-deoxyglucose autoradiography (Sokoloff et al, 1977), akin to that of FDG-PET used in humans (Phelps et al, 1979), to measure the effect of chronic intermittent exposure to PCP on local cerebral glucose utilization (LCGU) in rats.”
MethodKrystal, J. H. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950030035004 · Cited by 3,330
Recent advances in the phencyclidine model of schizophrenia
(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.10.1301 · Cited by 2,904
Ongur, D. (2000) · Cerebral Cortex · doi:10.1093/cercor/10.3.206 · Cited by 2,627
Glutamate receptor dysfunction and schizophrenia
Olney, J. W. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950240016004 · Cited by 1,685 · cited 2×
“Furthermore, it has been demonstrated that some effects of NMDA receptor antagonists (such as neurotoxicity) in rats are agedependent (Farber et al, 1995; Olney and Farber, 1995), which reflects a similar scenario in humans in relation to the onset of sensitivity to the psychotomimetic effects of Received 28 February…”
BackgroundNMDA receptor hypofunction model of schizophrenia
Olney, J. W., Newcomer, J. W., & Farber, N. B. (1999) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(99)00029-1 · Cited by 1,020 · cited 1×
“The past decade has gone beyond the dopamine hypothesis and has led to the postulation that glutamatergic hypofunction and the subsequent disruption of the tonic influence of GABA may play a pivotal role in schizophrenia (Lewis, 2000; Olney et al, 1999; Tamminga, 1998).”
BackgroundStudy of a New Schizophrenomimetic Drug—Sernyl
LUBY, E. D. (1959) · Archives of Neurology And Psychiatry · doi:10.1001/archneurpsyc.1959.02340150095011 · Cited by 921
Parvalbumin-immunoreactive neurons are reduced in the prefrontal cortex of schizophrenics
BEASLEY, C., & REYNOLDS, G. (1997) · Schizophrenia Research · doi:10.1016/s0920-9964(96)00122-3 · Cited by 426 · cited 1×
“Furthermore, these chandelier cells also contain the calcium-binding protein parvalbumin (Conde et al, 1994), which has also been shown to be decreased in schizophrenic post-mortem tissue within the prefrontal cortex and the anterior thalamus (Beasley and Reynolds, 1997; Danos et al, 1998).”
BackgroundGABAergic local circuit neurons and prefrontal cortical dysfunction in schizophrenia
Lewis, D. (2000) · Brain Research Reviews · doi:10.1016/s0165-0173(99)00042-9 · Cited by 257 · cited 3×
“…treatment on a particular neurochemical marker, parvalbumin, that has also been shown to be altered in post-mortem tissue from schizophrenic brains (Lewis, 2000; Pierri et al, 1999; Ohnuma et al, 1999; Danos et al, 1998) was also investigated within certain brain structures that have altered…”
Background
Cited by
Lisman, J. E., Coyle, J. T., Green, R. W., Javitt, D. C., Benes, F. M., Heckers, S., & Grace, A. A. (2008) · Trends in Neurosciences · doi:10.1016/j.tins.2008.02.005 · Cited by 1,010
“In vivo treatment with NMDAR antagonists for several days produces a reduction in cortical GAD67 and parvalbumin mRNA [76,77], much like that seen in schizophrenia (see above).”
BackgroundAnimal models of schizophrenia
Jones, C., Watson, D., & Fone, K. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01386.x · Cited by 771
Postnatal NMDA receptor ablation in corticolimbic interneurons confers schizophrenia-like phenotypes
Belforte, J. E., Zsiros, V., Sklar, E. R., Jiang, Z., Yu, G., Li, Y., Quinlan, E. M., & Nakazawa, K. (2010) · Nature Neuroscience · doi:10.1038/nn.2447 · Cited by 752
Neill, J. C., Barnes, S., Cook, S., Grayson, B., Idris, N. F., McLean, S. L., Snigdha, S., Rajagopal, L., & Harte, M. K. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2010.07.004 · Cited by 530
GABAergic interneuron origin of schizophrenia pathophysiology
Nakazawa, K., Zsiros, V., Jiang, Z., Nakao, K., Kolata, S., Zhang, S., & Belforte, J. E. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.01.022 · Cited by 498
“Third, repeated administration of NMDAR antagonists decreases the expression of GAD67 and PV in cortical GABAergic neurons (Cochran et al., 2003; Keilhoff et al., 2004; Rujescu et al., 2006; Behrens et al., 2007; Morrow et al., 2007), linking NMDAR hypofunction to dysfunction of GABAergic neurons.”
BackgroundHashimoto, T., Arion, D., Unger, T., Maldonado-Avilés, J. G., Morris, H. M., Volk, D. W., Mirnics, K., & Lewis, D. A. (2008) · Molecular Psychiatry · doi:10.1038/sj.mp.4002011 · Cited by 490
“The effects of chronic PCP exposure were a reduction in the expression level of PV mRNA per neuron by 25% without any change in the density of PV mRNA-positive neurons in the rat frontal cortex (Cochran et al., 2003).”
BackgroundNeurochemical markers for schizophrenia, bipolar disorder, and major depression in postmortem brains
Torrey, E. F., Barci, B. M., Webster, M. J., Bartko, J. J., Meador-Woodruff, J. H., & Knable, M. B. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.10.019 · Cited by 426
Cognitive Dysfunction in Schizophrenia: Convergence of γ-Aminobutyric Acid and Glutamate Alterations
Lewis, D. A., & Moghaddam, B. (2006) · Archives of Neurology · doi:10.1001/archneur.63.10.1372 · Cited by 404
Review: Glutamate and dopamine dysregulation in schizophrenia — a synthesis and selective review
Stone, J. M., Morrison, P. D., & Pilowsky, L. S. (2007) · Journal of Psychopharmacology · doi:10.1177/0269881106073126 · Cited by 348
An expanding range of targets for kynurenine metabolites of tryptophan
Stone, T. W., Stoy, N., & Darlington, L. G. (2013) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2012.09.006 · Cited by 344
Models of schizophrenia in humans and animals based on inhibition of NMDA receptors
Bubeníková-Valešová, V., Horáček, J., Vrajová, M., & Höschl, C. (2008) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2008.03.012 · Cited by 336
Kinney, J. W., Davis, C. N., Tabarean, I., Conti, B., Bartfai, T., & Behrens, M. M. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.4722-05.2006 · Cited by 329
“It is possible that a chronic hypoglutamatergic condition at the level of the cortico - limbo - thalamic circuitry , created by repetitive exposure to PCP or ketamine , reflects the long - term effects of a diminished exci - tatory drive on the phenotypic characteristics of these interneu - rons , as proposed recently…”
BackgroundInfluentialPathophysiologically based treatment interventions in schizophrenia
Lewis, D. A., & Gonzalez-Burgos, G. (2006) · Nature Medicine · doi:10.1038/nm1478 · Cited by 323
PCP: from pharmacology to modelling schizophrenia
Morris, B. J., Cochran, S. M., & Pratt, J. A. (2005) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2004.08.008 · Cited by 308
Self-citationReviewing the ketamine model for schizophrenia
Frohlich, J., & Van Horn, J. D. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881113512909 · Cited by 303
The kynurenine pathway as a therapeutic target in cognitive and neurodegenerative disorders
Stone, T. W., & Darlington, L. G. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12230 · Cited by 271
Mouri, A., Noda, Y., Enomoto, T., & Nabeshima, T. (2007) · Neurochemistry International · doi:10.1016/j.neuint.2007.06.019 · Cited by 266
The Thalamic Reticular Nucleus and Schizophrenia
Ferrarelli, F., & Tononi, G. (2011) · Schizophrenia Bulletin · doi:10.1093/schbul/sbq142 · Cited by 244
“These attentional impairments were associated with reduced expression of Zif-268 and parvalbumin, 2 markers of local neuronal activity, in the infralimbic cortex and in the TRN. 54 Other pharmacological studies investigating the effects of PCP on the rat brain found induced metabolic hypo-function within the prefronta…”
BackgroundInterleukin-6 Mediates the Increase in NADPH-Oxidase in the Ketamine Model of Schizophrenia
Behrens, M. M., Ali, S. S., & Dugan, L. L. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.4457-08.2008 · Cited by 241
“…include depression in brain metabolic activity in the prefrontal cortex (PFC), as well as within structures of the auditory system and the reticular nucleus of the thalamus, and resemble more closely the alterations observed in schizophrenia patients (Jentsch and Roth, 1999; Cochran et al., 2003).”
InfluentialAbdul-Monim, Z., Neill, J. C., & Reynolds, G. P. (2007) · Journal of Psychopharmacology · doi:10.1177/0269881107067097 · Cited by 206
Deidda, G., Bozarth, I. F., & Cancedda, L. (2014) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2014.00119 · Cited by 192
Cunningham, M. O., Hunt, J., Middleton, S., LeBeau, F. E. N., Gillies, M. G., Davies, C. H., Maycox, P. R., Whittington, M. A., & Racca, C. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.5054-05.2006 · Cited by 188
“Other models of psychosis in rodents have reported specific reductions in parvalbumin-positive interneurons in prelimbic areas (Cochran et al., 2002, 2003), so we examined whether the decrease in functional inhibition seen in mEC tissue from LPA1 Ϫ/Ϫ mice also could be attributable to a reduction…”
BackgroundCadinu, D., Grayson, B., Podda, G., Harte, M. K., Doostdar, N., & Neill, J. C. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.11.045 · Cited by 168
“NMDARs located on the interneurons have been implicated in modulating oscillations in the gamma frequency range (Cohen et al., 2015, Jadi et al., 2016) disturbances of which are observed in both pharmacological and genetic models (Carlen et al., 2012) of NMDAR hypofunction in schizophrenia (Jadi et…”
BackgroundBehrens, M. M., & Sejnowski, T. J. (2009) · Neuropharmacology · doi:10.1016/j.neuropharm.2009.06.002 · Cited by 162
“ular nucleus of the thalamus (Cochran et al., 2003).”
Wang, C. Z., Yang, S. F., Xia, Y., & Johnson, K. M. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301647 · Cited by 161
Rotaru, D. C., Yoshino, H., Lewis, D. A., Ermentrout, G. B., & Gonzalez-Burgos, G. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.1970-10.2011 · Cited by 151
Mechanisms of Action and Persistent Neuroplasticity by Drugs of Abuse
Korpi, E. R., den Hollander, B., Farooq, U., Vashchinkina, E., Rajkumar, R., Nutt, D. J., Hyytiä, P., & Dawe, G. S. (2015) · Pharmacological Reviews · doi:10.1124/pr.115.010967 · Cited by 148
Tseng, K. Y., Lewis, B. L., Hashimoto, T., Sesack, S. R., Kloc, M., Lewis, D. A., & O'Donnell, P. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.4166-08.2008 · Cited by 144
“In control animals, the cortical expression patterns of GAD67 and PV mRNAs were consistent with previous observations in rodents (de Lecea et al., 1995; Cochran et al., 2003; Lipska et al., 2003; Hashimoto et al., 2005) (Fig.”
ResultRodefer, J. S., Nguyen, T. N., Karlsson, J.-J., & Arnt, J. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301654 · Cited by 126
“However, the face validity of our model is augmented by previous reports of schizophrenia-like pathology, such as decreased parvalbumin expression (Abdul-Monim et al, 2007) and cortical metabolic hypofunction (Cochran et al, 2003) following PCP administration.”
BackgroundMethodCabungcal, J.-H., Nicolas, D., Kraftsik, R., Cuénod, M., Do, K. Q., & Hornung, J.-P. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2006.01.003 · Cited by 96
Gamma oscillation deficits and the onset and early progression of schizophrenia
Woo, T.-U. W., Spencer, K., & McCarley, R. W. (2010) · Harvard Review of Psychiatry · doi:10.3109/10673221003747609 · Cited by 96
Gomes, F. V., Issy, A. C., Ferreira, F. R., Viveros, M.-P., Del Bel, E. A., & Guimarães, F. S. (2015) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyu041 · Cited by 89
Jeevakumar, V., Driskill, C., Paine, A., Sobhanian, M., Vakil, H., Morris, B., Ramos, J., & Kroener, S. (2015) · Behavioural Brain Research · doi:10.1016/j.bbr.2015.01.010 · Cited by 84
Self-citationWang, X., Pinto-Duarte, A., Sejnowski, T. J., & Behrens, M. M. (2013) · Antioxidants & Redox Signaling · doi:10.1089/ars.2012.4907 · Cited by 46
Janhunen, S. K., Svärd, H., Talpos, J., Kumar, G., Steckler, T., Plath, N., Lerdrup, L., Ruby, T., Haman, M., Wyler, R., et al. (2015) · Psychopharmacology · doi:10.1007/s00213-015-3954-6 · Cited by 43
“…has been reported in the hippocampal regions at 6 weeks after the cessation of scPCP (Schroeder et al. 2000; AbdulMonim et al. 2007; Jenkins et al. 2008; Jenkins et al. 2010), while Cochran et al. (2003) reported a parvalbumin loss in the prefrontal cortex at 72 h post-scPCP (Table 2).”
BackgroundInfluentialParvalbumin Promoter Hypermethylation in Postmortem Brain in Schizophrenia
Fachim, H. A., Srisawat, U., Dalton, C. F., & Reynolds, G. P. (2018) · Epigenomics · doi:10.2217/epi-2017-0159 · Cited by 41
Egerton, A., Fusar-Poli, P., & M. Stone, J. (2012) · Current Pharmaceutical Design · doi:10.2174/138161212799316244 · Cited by 36
Fachim, H. A., Srisawat, U., Dalton, C. F., Harte, M. K., Marsh, S., Neill, J. C., & Reynolds, G. P. (2016) · Epigenomics · doi:10.2217/epi-2016-0050 · Cited by 22
Aberrant regulation of NMDA receptors by dopamine D4 signaling in rats after phencyclidine exposure
Wang, X., Gu, Z., Zhong, P., Chen, G., Feng, J., & Yan, Z. (2006) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2005.08.018 · Cited by 16
Metadata
- Authors
- Cochran, S. M., Kennedy, M., McKerchar, C. E., Steward, L. J., Pratt, J. A., & Morris, B. J.
- Venue
- Neuropsychopharmacology
- Published
- 2003-02
- Volume
- 28
- Issue
- 2
- Pages
- 265-275
- ISSN
- 0893-133X (ISSN-L)
- 1740-634X
- OpenAlex
- W2032529587
- Cited by
- 236
- References
- 9
- FWCI
- 4.67
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.